MA29787B1 - Traitement de maladies auto-immunes - Google Patents

Traitement de maladies auto-immunes

Info

Publication number
MA29787B1
MA29787B1 MA30758A MA30758A MA29787B1 MA 29787 B1 MA29787 B1 MA 29787B1 MA 30758 A MA30758 A MA 30758A MA 30758 A MA30758 A MA 30758A MA 29787 B1 MA29787 B1 MA 29787B1
Authority
MA
Morocco
Prior art keywords
autoimmune diseases
treatment
methods
sclerosis
ureity
Prior art date
Application number
MA30758A
Other languages
English (en)
Inventor
Rainer Albert
Nigel Graham Cooke
Barbara Nuesslein-Hildesheim
Sven Weiler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29787B1 publication Critical patent/MA29787B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Abstract

L'INVENTION PORTE SUR DES MÉTHODES DE TRAITEMENT DE DIVERSES MALADIES AUTO-IMMUNES, TELLES QUE LA SCLÉROSE EN PLAQUE, LA NÉVRITE PÉRIPHÉRIQUE, LA NÉVRITE OPTIQUE, LA SCLÉROSE AMYOTROPHIQUE LATÉRALE ET L'UVÉITE, CES MÉTHODES UTILISANT DES DÉRIVÉS AMINO-ALCOOL SPÉCIFIQUES.
MA30758A 2005-09-09 2008-03-17 Traitement de maladies auto-immunes MA29787B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71599005P 2005-09-09 2005-09-09

Publications (1)

Publication Number Publication Date
MA29787B1 true MA29787B1 (fr) 2008-09-01

Family

ID=37056992

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30758A MA29787B1 (fr) 2005-09-09 2008-03-17 Traitement de maladies auto-immunes

Country Status (29)

Country Link
US (1) US20080200438A1 (fr)
EP (2) EP1926483B1 (fr)
JP (4) JP5244598B2 (fr)
KR (3) KR20140117704A (fr)
CN (1) CN101257899B (fr)
AT (1) ATE489948T1 (fr)
AU (2) AU2006289100B2 (fr)
BR (1) BRPI0615906A2 (fr)
CA (2) CA2620554C (fr)
CY (1) CY1111285T1 (fr)
DE (1) DE602006018629D1 (fr)
DK (2) DK1926483T3 (fr)
ES (2) ES2357426T3 (fr)
HK (1) HK1149906A1 (fr)
IL (2) IL189665A (fr)
JO (1) JO2655B1 (fr)
MA (1) MA29787B1 (fr)
MX (1) MX2008003170A (fr)
NO (1) NO20081727L (fr)
NZ (2) NZ566137A (fr)
PL (2) PL2295049T3 (fr)
PT (2) PT2295049E (fr)
RU (2) RU2424795C2 (fr)
SG (1) SG165364A1 (fr)
SI (2) SI1926483T1 (fr)
TN (1) TNSN08103A1 (fr)
TW (2) TWI376223B (fr)
WO (1) WO2007028821A2 (fr)
ZA (1) ZA200801694B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007000564A (es) * 2004-07-16 2007-03-30 Kyorin Seiyaku Kk Metodo para utilizar efectivamente medicamentos referentes a la prevencion de efectos secundarios.
PL1806338T3 (pl) 2004-10-12 2016-07-29 Kyorin Seiyaku Kk Sposób wytwarzania chlorowodorku 2-amino-2-[2-[4-(3-benzyloksyfenylotio)-2-chlorofenyio]etylo]-1,3-propanodioiu i jego hydratów oraz produkty pośrednie w ich wytwarzaniu
WO2007043433A1 (fr) * 2005-10-07 2007-04-19 Kyorin Pharmaceutical Co., Ltd. Agent therapeutique destine a une maladie du foie contenant un derive 2-amino-1,3-propanediol servant de principe actif, et methode therapeutique associee destinee a une maladie hepatique
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
MY146775A (en) * 2006-08-08 2012-09-28 Kyorin Seiyaku Kk Amino alcohol derivative and immunosuppressive agent having same as an active ingredient
DK2058317T3 (da) * 2006-08-08 2014-01-06 Kyorin Seiyaku Kk Aminophosphorsyreesterderivat og S1P receptormodulator indeholdende samme som aktiv ingrediens
JP5198293B2 (ja) * 2007-02-13 2013-05-15 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
MX2010012676A (es) * 2008-05-20 2011-05-10 Kyorin Seiyaku Kk Agente para mantenimiento de remision inducida.
KR20110049870A (ko) * 2008-08-18 2011-05-12 노파르티스 아게 탈수초성 말초 신경병증의 치료를 위한 아미노 알콜 유도체
NZ603999A (en) * 2010-05-06 2014-06-27 Novartis Ag Treatment of autoimmune diseases
CN102917698A (zh) * 2010-05-06 2013-02-06 诺瓦提斯公司 二芳基硫醚衍生物的给药方案

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141421A (en) * 1991-12-17 1992-08-25 Carrier Corporation Nested coupling mechanism for scroll machines
DE4428835A1 (de) * 1994-08-01 1996-02-08 Schering Ag Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
PT990440E (pt) * 1997-02-27 2009-02-05 Novartis Ag Composição farmacêutica compreendendo 2-amino-2-[2-(4-octilfenil)etil]propano-1,3-diol, uma lecitina e um sacárido
MXPA04002679A (es) * 2001-09-27 2004-07-30 Kyorin Seiyaku Kk Derivados de sulfuro de diarilo, sales de los mismos y agentes inmunosupresores que utilizan los mismos.
WO2003029184A1 (fr) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Derive d'ether de diaryle, son sel d'addition et son immunosuppresseur
BR0314455A (pt) 2002-09-19 2005-07-26 Kyorin Seiyaku Kk Derivados de aminoálcool, seus sais e agentes imunosupressores
RU2391094C2 (ru) * 2002-09-24 2010-06-10 Новартис Аг Применение агониста рецептора s1p и способ лечения, облегчения или задержки прогрессирования неврита зрительного нерва или демиелинизационных заболеваний
RU2005108577A (ru) * 2002-09-28 2006-06-10 МакНЕЙЛ-ППС, ИНК. (US) Дозированные формы с модифицированным высвобождением
EP2172472B1 (fr) * 2003-02-18 2012-12-26 Kyorin Pharmaceutical Co., Ltd. Dérivé d'acide aminophosphonique et son sel d'addition et modulateur du récepteur S1P
PL1613288T3 (pl) * 2003-04-08 2009-07-31 Novartis Ag Stała kompozycja farmaceutyczna zawierająca agonistę receptora S1P oraz alkohol cukrowy
WO2005014525A2 (fr) * 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Compose bi-aryle presentant une activite immunosuppressive
US7528120B2 (en) * 2003-08-28 2009-05-05 Novartis Ag Aminopropanol derivatives
MX2007000564A (es) * 2004-07-16 2007-03-30 Kyorin Seiyaku Kk Metodo para utilizar efectivamente medicamentos referentes a la prevencion de efectos secundarios.
CA2589265A1 (fr) * 2004-11-29 2006-06-01 Novartis Ag Posologie d'un agoniste du recepteur s1p
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP5244598B2 (ja) 2013-07-24
NZ566137A (en) 2011-05-27
RU2008113187A (ru) 2009-10-20
PT2295049E (pt) 2015-03-02
ES2357426T3 (es) 2011-04-26
JP2009507810A (ja) 2009-02-26
CY1111285T1 (el) 2015-08-05
IL189665A0 (en) 2008-06-05
CA2820510A1 (fr) 2007-03-15
NZ588372A (en) 2012-03-30
EP1926483A2 (fr) 2008-06-04
PT1926483E (pt) 2011-03-03
PL1926483T3 (pl) 2011-05-31
IL233328A0 (en) 2014-08-31
TW200803829A (en) 2008-01-16
NO20081727L (no) 2008-06-06
KR101476451B1 (ko) 2014-12-24
ATE489948T1 (de) 2010-12-15
KR101476591B1 (ko) 2014-12-24
US20080200438A1 (en) 2008-08-21
TW201034659A (en) 2010-10-01
RU2424795C2 (ru) 2011-07-27
SG165364A1 (en) 2010-10-28
RU2493840C2 (ru) 2013-09-27
WO2007028821A3 (fr) 2007-05-03
CN101257899A (zh) 2008-09-03
JP2013010802A (ja) 2013-01-17
MX2008003170A (es) 2008-03-18
BRPI0615906A2 (pt) 2011-05-31
WO2007028821A2 (fr) 2007-03-15
CN101257899B (zh) 2012-10-03
EP2295049B1 (fr) 2014-11-26
DE602006018629D1 (de) 2011-01-13
JP2017019854A (ja) 2017-01-26
TNSN08103A1 (en) 2009-07-14
ES2529724T3 (es) 2015-02-25
AU2010224355B2 (en) 2012-03-29
EP2295049A1 (fr) 2011-03-16
PL2295049T3 (pl) 2015-04-30
JP6077265B2 (ja) 2017-02-08
AU2006289100A1 (en) 2007-03-15
JO2655B1 (en) 2012-06-17
CA2620554A1 (fr) 2007-03-15
DK1926483T3 (da) 2011-03-14
KR20140117704A (ko) 2014-10-07
AU2006289100B2 (en) 2010-07-22
IL189665A (en) 2014-07-31
JP2015025002A (ja) 2015-02-05
EP1926483B1 (fr) 2010-12-01
HK1149906A1 (en) 2011-10-21
DK2295049T3 (en) 2015-02-23
ZA200801694B (en) 2009-09-30
RU2011111117A (ru) 2012-09-27
SI2295049T1 (sl) 2015-03-31
AU2010224355A1 (en) 2010-10-14
TWI376223B (en) 2012-11-11
KR20080046231A (ko) 2008-05-26
KR20140019033A (ko) 2014-02-13
TWI372620B (en) 2012-09-21
SI1926483T1 (sl) 2011-04-29
CA2620554C (fr) 2013-12-17

Similar Documents

Publication Publication Date Title
MA29787B1 (fr) Traitement de maladies auto-immunes
BRPI0511875A (pt) uso de compostos de peptìdeo para tratamento da esclerose lateral amiotrófica
DK1754707T3 (da) Multicykliske forbindelser og anvendelse deraf som inhibitorer af PARP-, VEGFR2- og MLK3-enzymer
ATE482936T1 (de) Als b-sekretase (bace)-hemmer nützliche 2-amino- chinazolinderivate
ATE483692T1 (de) Als beta-sekretase (bace)-hemmer nützliche 2- amino-chinazolinderivate
EP1841426A4 (fr) Carbinamines tertiaires incluant des heterocycles substitues, agissant en tant qu'inhibiteurs de la beta-secretase et utilisees dans le traitement de la maladie d'alzheimer
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
UY26813A1 (es) Compuestos para tratar enfermedad de alzheimer
CR8230A (es) Sondas para enfermedades en las cuales se acumula amiloide, agentes para tincion del amiloide, farmacos para tratamiento y profilaxis de enfermedades con amiloide acumulado y sondas para diagnostico de ovillos neuro fibrilares yagentes...
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
CY1108221T1 (el) Μεθοδος για την αναπαραγωγη πλευρομουτιλινων
BRPI0408491A (pt) tratamento da doença de alzheimer
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
EA200701584A1 (ru) Органические соединения, применяемые для лечения болезни альцгеймера, их применение и способ получения
EA200800890A1 (ru) Модуляторы гексагидроциклогептапиразол каннабиноида
ATE519740T1 (de) Tetrahydroindolderivate zur behandlung von alzheimer-krankheit
MA29587B1 (fr) Compositions et methodes de diagnostic et de traitement de tumeur
BRPI0509881A (pt) combinação terapêutica para tratamento da doença de alzheimer
CY1116051T1 (el) Θεραπεια αυτοανοσων ασθενειων
BR0309110A (pt) composições e processo de tratamento da doença de alzheimer
EA200600534A1 (ru) Сочетание ингибитора обратного захвата серотонина и амоксапина